Bahl & Gaynor Inc. Buys 5,207 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bahl & Gaynor Inc. increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 125,599 shares of the medical instruments supplier’s stock after acquiring an additional 5,207 shares during the period. Bahl & Gaynor Inc.’s holdings in LeMaitre Vascular were worth $7,129,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Linden Thomas Advisory Services LLC raised its position in shares of LeMaitre Vascular by 2.9% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 29,996 shares of the medical instruments supplier’s stock worth $1,703,000 after acquiring an additional 839 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in LeMaitre Vascular by 251.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,875 shares of the medical instruments supplier’s stock worth $617,000 after purchasing an additional 7,782 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in LeMaitre Vascular during the 4th quarter valued at about $562,000. Shaker Investments LLC OH bought a new position in shares of LeMaitre Vascular in the 4th quarter valued at about $766,000. Finally, Conestoga Capital Advisors LLC boosted its stake in shares of LeMaitre Vascular by 0.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock valued at $109,432,000 after purchasing an additional 10,390 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

LMAT stock traded up $2.47 during midday trading on Friday, reaching $65.46. 117,291 shares of the company were exchanged, compared to its average volume of 111,857. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $74.64. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 48.85, a price-to-earnings-growth ratio of 2.76 and a beta of 0.87. The business has a 50-day moving average price of $65.35 and a two-hundred day moving average price of $58.10.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.02. The company had revenue of $48.90 million for the quarter, compared to analysts’ expectations of $49.01 million. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. LeMaitre Vascular’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the business earned $0.25 earnings per share. As a group, analysts anticipate that LeMaitre Vascular, Inc. will post 1.66 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Thursday, March 14th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Wednesday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a yield of 0.98%. LeMaitre Vascular’s payout ratio is presently 47.76%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and raised their price objective for the company from $59.00 to $75.00 in a research note on Friday. KeyCorp started coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a “sector weight” rating for the company. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, Barrington Research boosted their target price on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.33.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,859 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $69.73, for a total transaction of $1,942,608.07. Following the completion of the sale, the chief executive officer now owns 2,255,737 shares in the company, valued at approximately $157,292,541.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the sale, the director now owns 5,309 shares in the company, valued at $358,357.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 27,859 shares of LeMaitre Vascular stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.73, for a total value of $1,942,608.07. Following the sale, the chief executive officer now directly owns 2,255,737 shares of the company’s stock, valued at approximately $157,292,541.01. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 114,036 shares of company stock worth $7,873,749. Company insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.